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1990 94, after the diagnosis of OI, one-year survival
probability is only 59.8% (95%CI 52.0 67.7%). The most
common OI’s are tuberculosis (40 50%), cryptococcosis
(25 40%), Pneumocystis carinii pneumonia PCP (10 20%),
toxoplasmosis (5 10%) and salmonellosis (5 10%). In the
northern part of Thailand, where Penicillium marneffei
is endemic, this infection is as common as tuberculosis,
indicating the importance of local endemic infection to be
recognized as AIDS-deﬁning illnesses. Cryptococcosis carries
the worst prognosis with 1-year survival probability of 31.9%
(16.8 48.1%).
Since HAART became available and ﬁnancially supported
by Thai Government in 2001, the morbidity and mortality
of HIV-infected persons have decreased remarkably. OI’s
has decreased and people living with AIDS/HIV survive
much longer. The emergence of drug-resistant HIV has
posed problems since the second line drugs are much more
expensive and not many to choose from. In addition, this
group can transmit drug-resistant HIV causing primary drug-
resistant HIV infection which will make it more difﬁcult to
choose the proper regimen without genotyping the virus.
Thus, strong prevention and control program should remain
at top priority, to stop new infection and transmission.
I-24 HIV-speciﬁc T-cell responses in a cohort of slow
progressors in China
T. Dong*. WIMM, Oxford University, United Kingdom
Background: There is an urgent need for an effective
vaccine to prevent HIV-1 infection, and current efforts are
directed towards generating vaccine candidates that will
elicit a T-cell immune response to the virus.. No studies
to date have described mechanisms of HIV resistance or
delayed disease progression in Chinese cohorts. For both
the design and the evaluation of CTL-inducing vaccines it is
important to deﬁne immunodominant CTL epitopes for both
the prevailing HLA types and the most common viral strains
affecting that population. Morever, it is also important to
identify composite features of T-cell responses associated
with good outcome and T-cell epitopes that will generate
such beneﬁcial features.
Study cohort: Current studies are limited by the facts that
most of the study cohort subjects have been infected for
different lengths of time; infected with different viral
strains and have a diverse genetic background. In this
study, we have access to a unique village cohort of patients
(N = 407) who were involved in a plasma donation scheme
that became contaminated with clade B HIV-1 in the period
1994 1995. 137 premature adult deaths were recorded in
the village with symptoms compatible with HIV-1 disease
before 2003. Of the surviving patients, none were treated
before 2003: therefore the proportion of slow or non-
progressors is unusually high in this cohort (>50% had CD4
counts >200 in 2004).
Results: We found that HLA-A30 and B51 were strongly
associated with low viral load in this cohort. We investigated
the hypothesis that immunodominant T-cell responses to
conserved HIV-1 proteins restricted by these alleles could
be partially responsible for good control of virus. We used
ELISPOT assays to test for responses to overlapping Clade B
peptides spanning the whole viral proteome and to the 202
best characterised optimal epitopes from the Los Alamos
data base. We found broad T cell responses, especially
directed towards the gag protein, in patients with low
viral loads. The immunodominance hierarchy of epitopes
restricted by common HLA molecules in the cohort showed
very different patterns from a published acute cohort
(Altfeld, 2006). We have sequenced the gag and nef genes
from 97 patients and will present data to show that the loss
of certain responses in the chronic phase of infection might
be due to early selection of escape mutants.
Conclusion: We have identiﬁed a panel of immunodominant
T-cell responses restricted by common HLA alleles in a
Chinese slow progressor cohort. Identiﬁcation of the most
beneﬁcial responses will be particular important for future
vaccine design targeted to the Chinese population.
I-25 Outcomes and challenges of the China National
Free Antiretroviral Treatment Program
F.J. Zhang*. National Center for AIDS/STD Control and
Prevention, Chinese Center for Disease Control and
Prevention, Beijing, China
To combat the HIV/AIDS epidemic in China, the National
Center for AIDS/STD Control and Prevention established the
Division of Treatment and Care in late 2001. The pilot for
the National Free ART Program began in Henan Province in
2002, and the program fully launched in 2003. Initially,
treatment efforts focused on patients infected through
illicit blood and plasma donations in the mid-1990s, and
subsequently expanded to include HIV-infected injection
drug users, commercial sex workers, pregnant women, and
children. The National Free ART Database was established
in late 2004, and includes data on current patients and
those who were treated before 2004. Over 50,000 adult and
pediatric patients have been treated thus far. Challenges
for the program include integration of drug treatment
services with ART, an under-resourced health care system,
co-infections, stigma, discrimination, drug resistance, and
procurement of second-line ART. The merging of national
treatment and care, epidemiologic, and drug resistance
databases will be critical for a better understanding of the
epidemic, earlier identiﬁcation of patients requiring ART,
and improved patient follow-up. The Free ART Program has
made considerable progress in providing the necessary care
and treatment for HIV-infected people in China and has
strong government support for continued improvement and
expansion.
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I-26 Immunology of HBV infection
J.M. Vierling*. Professor of Medicine and Surgery, Chief
of Hepatology, Baylor College of Medicine, Houston, TX,
USA
HBV is an enveloped, hepatotrophic, oncogenic
hepadnavirus that infects hepatocytes and leukocytes
of humans and chimpanzees. The clinicopathological
outcomes of HBV infection are determined by both
viral and host factors. HBV infects hepatocytes without
triggering apoptosis, altering hepatocyte gene expression
or inducing innate immune production of IFNa or IFNb.
Host determinants of outcomes are the quality, quantity,
kinetics and immunoregulation of the integrated innate
and adaptive immune responses. HBV subverts the innate
immune response by down-regulating (1) expression of MICA,
the primary ligand for the NKG2D receptors of NK cells and
(2) TLR1, 2, 4 and 6 transcripts in PBMC. In addition, HBV
persistence and disease progression is favored by the low
production of mannose binding lectin (MBL) and reduction
in the interferon-inducible APOBEC3 family of cytidine
deaminases that inhibit HBV replication and hypermutate
the HBV genome. Generation of polyclonal, multi-antigen-
speciﬁc CD4 T-cell and CD8 cytotoxic T lymphocytes (CTL)
is required for resolution of acute HBV infection through
the combined effects of HBV-speciﬁc cytolysis of infected
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hepatocytes and secretion of proinﬂammatory cytokines
IFNg and TNFa to inhibit HBV replication noncytolytically.
Since these inhibitory cytokines are produced not only
by CTL, but also by enriched, activated populations of
hepatic NK and NKT-cells, it is now clear that NK and
NKT-cells contribute to resolution of acute hepatitis B.
HBV-speciﬁc T-cell immune responses are also modulated by
CD4 T regulatory cells. The role of HBV-speciﬁc antibodies
in resolution is less clear; however, once acute infection
is resolved the combination of HBV-speciﬁc cellular and
humoral immunity prevents reactivation of HBV replication
from residual nuclear cccDNA templates. The risk of
reactivation remains if immunological control is disrupted
by immunosuppressive drugs or cytoablative chemotherapy.
Persistent HBV infection, which occurs in the majority
of neonates and infants but only a minority of adults,
is favored by several viral and host factors. The viral
factors include the subversion of innate immunity, a high
rate of replication favoring mutational escape, absence
of hepatocyte gene induction, tolerogenic properties of
secreted HBeAg and HBsAg, HBx inhibition of proteasome
processing of antigens and HBx induction of aberrant
class II MHC and ICAM-1 to favor clonal T-cell anergy
due to absence of costimulatory signaling. Host factors
associated with persistence include decreased numbers
and defective function of plasmacytoid-dendritic cells,
decreased expression of TLR and class I MHC, decreased
production of MDL and APOBEC3 cytidine deaminases,
CTLA-4 polymophorisms, CD4 T regulatory cell activity and
CTL suppression mediated by paracrine activation of PD-1.
Overall, chronic hepatitis B is associated with a paucity
of HBV-speciﬁc CTL, activated HBV-speciﬁc CD4 T helper 1
cells and hepatic inﬂammatory inﬁltrates enriched for NK,
NKT and other antigen-nonspeciﬁc cells. Perpetuation of
antigen-nonspeciﬁc inﬂammation favors progressive ﬁbrosis.
Better understanding of the immunopathogenesis of HBV
infection has also provided insights into the mechanisms
responsible for ﬂares during chronic infection, reactivation
following immunosuppression or chemotherapy, vasculitis
and recurrent HBV infection after liver transplantation.
Ultimately, complete understanding of the immunology of
HBV infection will likely lead to new therapeutic strategies.
I-27 New cell culture and mouse models of
HBV replication
H. Tang. Department of Infectious Diseases, West China
Hospital of Sichuan University, Chengdu, Sichuan, China
Hepatitis B virus (HBV) infection is a worldwide health
problem. Understanding of the HBV life cycle especially the
replication mechanism may provide potential targets for
the development of anti-HBV treatment. Cell culture and
animal models with HBV replication are the most important
tools for studies on the mechanism of HBV replication, the
pathogenesis of HBV-related liver diseases, and the selection
of anti-HBV drugs.
Hepatotropism is a prominent feature of hepatitis B virus
(HBV) infection. Cell lines of non-hepatic origin do not
independently support HBV replication hepatic origin. In
our study, a new HBV nonhepatoma cell replication system
has been developed where pregenomic RNA synthesis
and consequently HBV replication are controlled by the
ectopic expression of liver-enriched transcription factors.
We show that the nuclear hormone receptors, hepatocyte
nuclear factor 4 (HNF4) or retinoid X receptor a (RXRa)
plus peroxisome proliferator-activated receptor a (PPARa),
support HBV replication in non-hepatic cells, indicating
these liver-enriched transcription factors represent a major
determinant governing the hepatotropism of HBV. With
this new HBV replication system, many roles of the
liver-enriched transcription factors in controlling HBV
transcription and replication have been identiﬁed.
Until recently, most in vivo studies on HBV have been
performed by using HBV transgenic mice. However, the
acquisition of transgenic mice is very time-consuming and
laborious, because expensive microinjection equipment and
complicated technology is needed. Recently, we developed
a new mouse model with HBV replication by using a
hydrodynamic procedure that provides a simple, convenient
and useful tool for molecular-biological studies on HBV, and
for the selection of anti-HBV drugs.
I-28 Association between epidermal growth factor gene
polymorphisms and the risk of hepatocellular
carcinoma in patients with hepatitis B virus chronic
infection
F.M. Lu, Y.J. Li, Q. Xie, H. Zhuang. Department of
Microbiology, Peking University Health Science Center,
Beijing, 100191, China
Aims: Epidermal growth factor (EGF) is a multifunctional
growth factor, and plays an important role in tumorigenesis,
including hepatocellular carcinoma (HCC). A single
nucleotide polymorphism (SNP) at position 61 in the 5′-
untranslated region (UTR) of the EGF gene has been
reported to modulate the transcription level of this gene
and is associated with the level of EGF protein expression in
serum or plasma. In present study the relationship between
EGF 61A/G polymorphism, EGF protein expression level,
and risk of HCC in patients with hepatitis B virus chronic
infection were assessed.
Materials and Methods: EGF gene 61A/G allele was
genotyped in ten human HCC cell lines and one immortalized
normal liver cell line. Furthermore, genomic DNA samples
from 195 HCC patients, 149 cirrhosis patients, and 186
healthy control subjects were also examined. Polymerase
chain reaction restriction fragment-length polymorphism
(PCR-RFLP) was used to determine the EGF polymorphism
genotype. EGF protein in different polymorphism genotype
from healthy control subjects was quantiﬁed by using an
enzyme-linked immmunosorbent assay (ELISA). HCC cell
lines with different polymorphic genotype were subjected
to growth assay in the presence of geﬁtinib, one EGFR
blocker.
Results: Six of the examined HCC cell lines were GG
genotype (HBxF344, Hep3B, SKHep1, SNU182, SNU387 and
SNU449), 3 were GA genotype (HepG2, PLC/PRF5 and
SMMC7721), SNU475 and the immortalized LO2 was AA
genotype. Allele frequencies of EGF SNP61*A and SNP61*G
in control group were 28.76% and 71.24%, while they
were 27.18% and 72.82%, 32.89% and 67.11% in HCC group
and cirrhosis group respectively. There was no signiﬁcant
difference in SNP61*A frequencies between hepatocellular
carcinoma group and healthy control group, as well as
cirrhosis group and healthy control group. And SNP61*A
frequencies in HCC group have no difference from cirrhosis
group, however, patients with a GA or GG genotype
had a respectively 2.3- and 1.9-fold odds of developing
hepatocellular carcinoma compared with patients with the
AA genotype, indicating that AA genotype may have lower
HCC risk. Concordantly, a signiﬁcant higher EGF protein
level in GG and GA genotype compared to AA genotype was
found. In addition, EGF gene polymorphisms at position 19,
101, 341 were also examined from 78 healthy subjects, 53
HCC patients, all were homozygote. In order to conﬁrm
whether EGFR blocker can affect the proliferation of cell
with different genotypes, six cell lines were treated by
geﬁtinib. We observed that cell proliferation of HBxF344,
SKHep1 with the GG genotype was reduced by geﬁtinib
